Trial reportThe Journal of infectious diseases2026
Efficacy of Praziquantel for Treatment of Plasmodium falciparum Infection in Asymptomatic Gabonese Adults: A Double-Blind Placebo-Controlled Randomized Trial.
Trial report in The Journal of infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
backgroundSchistosomiasis and malaria are major poverty-related parasitic infectious diseases. They are often coendemic and affect similar target populations. Mass drug administration and intermittent preventive treatment programs are commonly used for their control. From a programmatic perspective the establishment of preventive treatment programs targeting both diseases simultaneously would be a great advantage. While there is preliminary evidence that certain antimalarial drugs exert a clinically important effect on Schistosomes, little is known on whether praziquantel (PZQ), the only licensed drug to treat schistosomiasis, has activity against Plasmodium parasites. Therefore, the CORMA-MAL study was conducted to evaluate antimalarial activity of PZQ.
methodsThis double-blinded, randomized, placebo-controlled phase 2b trial was conducted in Lambaréné, Gabon and recruited semi-immune adults with an asymptomatic Plasmodium falciparum parasitemia. Participants were randomized (1:1) to receive placebo or 40 mg/kg PZQ once daily for 3 days and followed up for a total of 7 days.
resultsForty-four participants were recruited. Analytical models indicated a highly significant hourly reduction of microscopically determined parasitemia in the PZQ arm and a nonsignificant decreasing trend in the placebo group (regression slopes of log10-transformed parasitemia: β=-0.006 [P < .001] and β=-0.0013 [P = .3], respectively). However, in total only 9 of 22 (41%) in the PZQ arm compared to 6 of 22 (27%) in the placebo arm reached parasite clearance by day 7.
conclusionsFindings demonstrate a statistically significant antimalarial activity of PZQ; however, the observed effect is only moderate compared to current first-line antimalarial treatments. Future research should investigate the synergistic potential of combining PZQ and antimalarial drugs in malaria and schistosomiasis control. Clinical Trials Registration.Pan African Clinical Trials Registry, PACTR202206584817951, 10 June 2022 (https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=22586).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.